Cellectar Biosciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CLRB and other ETFs, options, and stocks.

About CLRB

Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124, which could detect tumors and metastases in a broad range of cancers, and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. 

CEO
James V. Caruso
CEOJames V. Caruso
Employees
11
Employees11
Headquarters
Florham Park, New Jersey
HeadquartersFlorham Park, New Jersey
Founded
1996
Founded1996
Employees
11
Employees11

CLRB Key Statistics

Market cap
21.41M
Market cap21.41M
Price-Earnings ratio
-0.57
Price-Earnings ratio-0.57
Dividend yield
Dividend yield
Average volume
30.32K
Average volume30.32K
High today
$2.64
High today$2.64
Low today
$2.56
Low today$2.56
Open price
$2.57
Open price$2.57
Volume
46.28K
Volume46.28K
52 Week high
$6.52
52 Week high$6.52
52 Week low
$2.20
52 Week low$2.20

Stock Snapshot

The current Cellectar Biosciences(CLRB) stock price is $2.60, with a market capitalization of 21.41M. The stock trades at a price-to-earnings (P/E) ratio of -0.57.

As of 2026-08-16, Cellectar Biosciences(CLRB) stock has fluctuated between $2.56 and $2.64. The current price stands at $2.60, placing the stock +1.6% above today's low and -1.4% off the high.

Cellectar Biosciences(CLRB) shares are trading with a volume of 46.28K, against a daily average of 30.32K.

In the last year, Cellectar Biosciences(CLRB) shares hit a 52-week high of $6.52 and a 52-week low of $2.20.

In the last year, Cellectar Biosciences(CLRB) shares hit a 52-week high of $6.52 and a 52-week low of $2.20.

CLRB News

TipRanks 2d
Cellectar: Solid Cash Runway and De-Risking Clinical Milestones Support Buy Rating; $10 Price Target Reiterated

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Cellectar Biosciences, with a price target of $10.00. Claim 55% Off T...

TipRanks 2d
Cellectar’s New Phase 3 WM Trial Puts Iopofosine I 131 on Investors’ Radar

Cellectar Biosciences Inc (CLRB) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, mo...

People also own

Based on the portfolios of people who own CLRB. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.